Comparison of the Therapeutic Effects of 5% Minoxidil Solution Alone with the Medicinal Combination of 5% Minoxidil and 0.005% Latanoprost in Men with Androgenetic Alopecia Referred to Skin Clinics of Isfahan University of Medical Sciences

Document Type : Original Article(s)

Authors

1 Assistant Professor of Dermatology, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor of Dermatology, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

3 Dermatologist, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

4 General Practitioner, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 MSc of Epidemiology, Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v42.i761.0209

Abstract

Background: This study aims to investigate and compare the therapeutic effects of 5% minoxidil solution alone with the combination of 5% minoxidil and 0.005% latanoprost in men with androgenetic alopecia referred to skin clinics of Isfahan University of Medical Sciences.
Methods: This study was a randomized, double-blind clinical trial on 50 male patients with androgenetic alopecia at Al-Zahra Hospital and Sediqeh Tahereh Center in Isfahan. Participants were randomly assigned to two groups of 25 people: one receiving minoxidil 5% and the other receiving a combination of latanoprost 0.005% and minoxidil 5%. Outcomes measured included patient improvement, hair loss reduction, hair growth increase, and patient satisfaction.
Findings: A total of 45 participants, with a mean age of 29.1+12.5 years, were studied. N Groups did not show significant differences in age, duration of illness, or percentage of head involvement. Treatment recovery rate, satisfaction, and drug side effects (peeling, erythema, hair loss, and itching) showed no significant differences between the two groups.
Conclusion: Generally, the present study showed no significant difference between the rate of recovery, satisfaction, and complications after treatment in both intervention groups of minoxidil 5% and the drug combination of latanoprost 0.005% and minoxidil 5%.

Highlights

Nazila Poostiyan: PubMed, Google Scholar

Gita Faghihi: PubMed, Google Scholar

Setayesh Sindarreh: PubMed, Google Scholar

Keywords

Main Subjects

References

  1. Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine 2017; 57(1): 9-17.
  2. Piraccini B, Alessandrini A. Androgenetic alopecia. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia. [1980]. Available from: https://catalogue.nla.gov.au/catalog/1978252
  3. Frith H, Jankowski GS. Psychosocial impact of androgenetic alopecia on men: A systematic review and
    meta-analysis. Psychol Health Med 2024; 29(4): 822-42.
  4. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 77(1): 136-41. e5.
  5. Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol 2014; 15(3): 217-30.
  6. Gupta AK, Foley KA. 5% Minoxidil: treatment for female pattern hair loss. Skin Therapy Lett 2014; 19(6): 5-7.
  7. Gupta AK, Charrette A. Topical minoxidil: systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed 2015; 13(3): 185-9.
  8. Jiang S, Hao Z, Qi W, Wang Z, Zhou M, Guo N. The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1130623.
  9. Kawen AA. Topical minoxidil alone and with topical lanoprost in localized alopecia areata treatment: comparative study (2019-2020). Systematic Reviews in Pharmacy 2020; 11(4).
  10. El-Ashmawy AA, El-Maadawy IH, El-Maghraby GM. Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata. J Dermatolog Treat 2018; 29(1): 55-64.
  11. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol 2002; 82(1): 7-12.
  12. Blume-Peytavi U, Lönnfors S, Hillmann K, Bartels NG. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012; 66(5): 794-800.
  13. Guarrera M, Cardo P, Arrigo P, Rebora A. Reliability of hamilton-norwood classification. Int J Trichology 2009; 1(2): 120-2.
  14. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14(4): 713-21.
  15. Goren A, Naccarato T, Situm M, Kovacevic M, Lotti T, McCoy J. Mechanism of action of minoxidil in the treatment of androgenetic alopecia is likely mediated by mitochondrial adenosine triphosphate synthase-induced stem cell differentiation. J Biol Regul Homeost Agents 2017; 31(4): 1049-53.
  16. Bloch LD, Escudeiro CC, Sarruf FD, Valente NYS. Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss. Surg Cosmet Dermatol 2018; 10(1): 41-5.
Journal of Isfahan Medical School
Volume 42, Issue 761
1st Week, June
May and June 2024
Pages 209-216

Files

History

  • Receive Date: 22 June 2022
  • Revise Date: 19 June 2024
  • Accept Date: 01 July 2024

Share

How to cite

Statistics